AURX · XBRL financial data

Nuo Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AURX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of goods and services sold	54	41*	51	65	101	86*	121	159	407	408*	452	599
Gross profit	178	—	184	299	270	—	363	541	625	—	850	1,170
Selling, general and administrative	968	808*	893	841	848	938*	1,109	1,193	1,166	1,268*	1,296	1,337
Total operating expenses	968	808*	893	841	848	938*	1,109	1,193	1,166	1,268*	1,296	1,337
Operating income (loss)	(790)	(652)*	(709)	(542)	(577)	(629)*	(745)	(652)	(540)	(579)*	(446)	(167)
Other income (expense)	0	0*	0	1	0	(1)*	1	1	2	2*	3	3
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(791)	(653)*	(709)	(540)	(578)	(497)*	(746)	(650)	(538)	(578)*	(618)	(278)
Earnings per share, basic USD per share	(0.02)	(0.02)*	(0.02)	(0.01)	(0.01)	(0.01)*	(0.02)	(0.01)	(0.01)	(0.01)*	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	42,142	42,562*	44,242	44,658	45,614	47,163*	46,816	46,823	47,539	48,056*	48,285	48,408

Fiscal quarters (AURX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	583	929	366	473	684	284	56	316	515	549	264	449
Accounts receivable	233	251	230	305	329	248	277	320	652	562	874	1,168
Inventory	210	210	211	217	168	150	99	166	202	214	249	270
Prepaid and other current assets	178	174	174	180	162	159	170	51	94	56	134	107
Total current assets	1,258	1,563	981	1,175	1,343	842	602	853	1,463	1,380	1,520	1,993
Property and equipment, net	49	45	41	42	189	177	392	370	347	366	345	572
Right-of-use asset	293	269	220	204	188	171	154	136	118	99	81	61
Total assets	1,600	1,878	1,243	1,420	1,719	1,190	1,147	1,359	1,928	1,846	1,946	2,626
Accounts payable	401	395	486	398	385	219	662	313	492	436	385	563
Accrued liabilities	196	189	215	230	264	292	350	315	391	494	593	619
Total current liabilities	685	675	761	690	714	578	1,281	999	1,256	1,306	1,369	1,554
Lease liability, non-current	188	164	148	132	115	97	79	60	41	21	0	0
Total liabilities	873	839	909	822	829	676	1,360	2,184	2,347	2,802	3,330	4,162
Accumulated deficit	(29,283)	(29,936)	(30,645)	(31,185)	(31,763)	(32,260)	(33,006)	(33,656)	(34,194)	(34,772)	(35,391)	(35,668)
Total stockholders' equity	727	1,039	333	599	890	514	(213)	(825)	(420)	(957)	(1,384)	(1,535)
Total liabilities and equity	1,600	1,878	1,243	1,420	1,719	1,190	1,147	1,359	1,928	1,846	1,946	2,626
Common shares outstanding (cover page) thousands of shares	42,317	44,242	44,242	45,466	46,598	46,816	46,820	46,831	48,078	48,289	48,409	48,434

Fiscal quarters (AURX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(791)	(653)*	(709)	(540)	(578)	(497)*	(746)	(650)	(538)	(578)*	(618)	(278)
Stock-based compensation	12*	3*	3	3*	21*	30*	19	23*	20*	24*	24	41*
Net cash from operating activities	(795)*	(671)*	(562)	(691)*	(487)*	(491)*	2	262*	(707)*	(423)*	(784)	(236)*
Purchases of property and equipment	2*	0*	0	4*	151*	0*	230	2*	0*	43*	1	253*
Net cash from investing activities	(2)*	0*	0	(4)*	(151)*	0*	(230)	(2)*	0*	(43)*	(1)	(253)*
Proceeds from issuing common stock	1,035*	963*	—	—	849*	0*	—	—	791*	0*	—	—
Net cash from financing activities	1,035*	963*	0	802*	849*	90*	0	0*	905*	500*	500	675*
Net change in cash	238*	291*	(562)	107*	211*	(400)*	(228)	261*	198*	34*	(285)	185*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Vicarious Surgical	1,407	not reported	(6,325)	not reported	0.6 quarters	Q1 FY26 10-QMar 31, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Modular Medical	3,920	not reported	(5,972)	8.2M	0.7 quarters	Q1 FY27 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
HeartBeam	8,722	not reported	(3,342)*	56.3M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.